Literature DB >> 29532140

A Prospective Comparative Study on Improvement of Hyperthyroid Cardiovascular Dysfunction in Patients Undergoing Total Thyroidectomy Versus Medical Management.

S Muthukumar1,2, K Ravikumar3,4, S Dhalapathy3,5, T Gomathy6,7, S Umadevi3, D Maruthupandian8.   

Abstract

INTRODUCTION: Cardiovascular dysfunction (CVD) is a well-recognized complication in patients with hyperthyroidism and is the major cause of mortality. Very few studies have compared the outcome of CVD following different treatment modalities. In this study we intended to compare treatment modalities (antithyroid drugs vs surgery) for reversal of CVD.
MATERIALS AND METHODS: Patients with newly detected hyperthyroidism were grouped into, Group I [n = 123, age <60 years, undergoing total thyroidectomy], Group II [n = 42, age <60 years, treated with antithyroid medications] were evaluated with 2D echocardiography, serum N terminal pro brain natriuretic peptide (NT-pro-BNP) at the time of diagnosis (Point A), after achieving euthyroidism (Point B) with antithyroid drugs and 6 months after surgery/continuation of antithyroid medications (Point C). Forty patients (Group III), age < 60 years, undergoing total thyroidectomy for nontoxic benign thyroid nodules served as controls.
RESULTS: All groups were age and sex matched. At Point A, CVD was evident in 80/123 (65%) in Group I and 28/42 (66.7%) in Group II. At Point B improvement in CVD occurred in 84/123 (68.3%) in Group and 29/42 (69.04%) in Group II. At Point C dramatic improvement in CVD occurred in 118/123 (95.9%) in Group I, whereas only 33/42 (78.5%) improved in Group II. CVD were comparable between Groups I and II at Point A and Point B (p > 0.05). At Point C there was a significant decrease in all the diastolic dysfunction parameters in Group I, whereas the same was not observed in Group II patients. Systolic dysfunction between Groups II and II had no statistical significance at Point C.
CONCLUSION: Total thyroidectomy seems to be the definitive treatment of choice for hyperthyroid cardiac dysfunction with diastolic dysfunction completely reversing at 6 months after TT.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29532140     DOI: 10.1007/s00268-018-4571-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  25 in total

Review 1.  Thyroid hormone and the cardiovascular system.

Authors:  I Klein; K Ojamaa
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

2.  Cardiovascular disease and thyroid function.

Authors:  Jens Faber; Christian Selmer
Journal:  Front Horm Res       Date:  2014-06-10       Impact factor: 2.606

3.  The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities.

Authors:  José A Sgarbi; Fábio G Villaça; Benito Garbeline; Heloísa E Villar; João H Romaldini
Journal:  J Clin Endocrinol Metab       Date:  2003-04       Impact factor: 5.958

Review 4.  A systematic review of drug therapy for Graves' hyperthyroidism.

Authors:  Prakash Abraham; Alison Avenell; Christine M Park; Wendy A Watson; John S Bevan
Journal:  Eur J Endocrinol       Date:  2005-10       Impact factor: 6.664

5.  Impact of thyroidectomy on cardiac manifestations of Graves' disease.

Authors:  Jason M Gauthier; Hossam Eldin Mohamed; Salem I Noureldine; Timo Z Nazari-Shafti; Tina K Thethi; Emad Kandil
Journal:  Laryngoscope       Date:  2016-03-01       Impact factor: 3.325

6.  Congestive heart failure and sudden death in a young woman with thyrotoxicosis.

Authors:  J A Magner; W Clark; P Allenby
Journal:  West J Med       Date:  1988-07

7.  Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study.

Authors:  J V Parle; P Maisonneuve; M C Sheppard; P Boyle; J A Franklyn
Journal:  Lancet       Date:  2001-09-15       Impact factor: 79.321

8.  Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery.

Authors:  Mirna Abraham-Nordling; Ove Törring; Bertil Hamberger; Göran Lundell; Leif Tallstedt; Jan Calissendorff; Göran Wallin
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

9.  Atrial fibrillation and hyperthyroidism.

Authors:  Jayaprasad N; Johnson Francis
Journal:  Indian Pacing Electrophysiol J       Date:  2005-10-01

10.  Echocardiographic assessment of left ventricular function in thyrotoxicosis and implications for the therapeutics of thyrotoxic cardiac disease.

Authors:  Raphael C Anakwue; Basden J Onwubere; Vincent Ikeh; Benedict Anisiuba; Samuel Ike; Angel-Mary C Anakwue
Journal:  Ther Clin Risk Manag       Date:  2015-02-05       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.